Journal of Human Reproductive Science
Home Ahead of Print Current Issue Archives
   Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size    Users online: 978


 
   Table of Contents     
CASE REPORT  
Year : 2021  |  Volume : 14  |  Issue : 4  |  Page : 443-445
 

Drug-free in vitro activation for primary ovarian insufficiency


Department of Reproductive Medicine and Akanksha Hospital and Research Institute, Anand, Gujarat, India

Date of Submission06-Apr-2021
Date of Decision25-May-2021
Date of Acceptance06-Sep-2021
Date of Web Publication31-Dec-2021

Correspondence Address:
Dr. Niket H Patel
Akanksha Hospital and Research Institute, Near Shristi English Medium School Opp. Guruvilla Bungalows, Lambhvel, Anand - 387 310, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jhrs.jhrs_56_21

Rights and Permissions

 

   Abstract 


Primary Ovarian Insufficiency (POI) or Diminished Ovarian Reserve (DOR) are the two conditions that affects women leading to infertility due to the lack of follicular growth and ovulation. Egg / Oocyte donation remains an option for these patients. However, with the development in Reproductive medicine various novel technologies like Ovarian Cryopreservation, Fragmentation, in vitro activation with drug treatment or even drug free autotransplantation enables the possibility of activating the pool of primordial follicles that can lead to successful pregnancy outcomes. Here, we report a case of women with POI, in which drug free in vitro activation of follicles was performed, followed by autotransplantation, which resulted in successful pregnancy. This is first case report from India that shows the procedure works and can be tried for women with POI.


Keywords: Drug-free, in vitro activation, infertility


How to cite this article:
Patel NH, Bhadarka HK, Patel NH, Patel MN. Drug-free in vitro activation for primary ovarian insufficiency. J Hum Reprod Sci 2021;14:443-5

How to cite this URL:
Patel NH, Bhadarka HK, Patel NH, Patel MN. Drug-free in vitro activation for primary ovarian insufficiency. J Hum Reprod Sci [serial online] 2021 [cited 2022 Aug 17];14:443-5. Available from: https://www.jhrsonline.org/text.asp?2021/14/4/443/334535





   Introduction Top


Over the recent decades, age-related decreased fertility has become an increasing challenge for infertility professionals. This 'natural infertility' occurs due to the exhaustion of the pool of resting ovarian primordial follicles.[1] Worldwide, 1% of women suffer from primary ovarian insufficiency (POI), which leads to early exhaustion of ovarian follicles due to genetic, immunological, iatrogenic, or any ovarian pathology. They are characterised by high circulating follicle-stimulating hormone (FSH) and experience amenorrhoea before the age of 40 years. For such patients the only option is to go for egg donation. The main aim of regenerative medicine is to activate the remaining ovarian 'reproductive gold reserve' for such patients and also in the patients of diminished ovarian reserve (DOR).[2] In recent years, different approaches have been established to regenerate, rejuvenate or reactivate germs cells in the ovary. For the activation of dormant follicles by utilising in vitro culture of ovarian fragments treated with phosphatidylinositol 3-kinase stimulators and phosphatase and tensin homologue inhibitors.[3] Other studies have suggested that ovarian fragmentation disrupts the Hippo signalling pathway leading to ovarian follicle growth.[4] A study by Kawamura et al. merged the two concepts and demonstrated that ovarian fragmentation promoted actin polymerisation and disrupted ovarian Hippo signalling that lead to the promotion of follicle growth followed by autotransplantation.[5] Fabregues et al. further suggested that drug-free ovarian activation of follicles using fresh tissue autotransplantation could be done in POI patients.[2]

Hereby, we present a case of a patient with POI in which pregnancy was achieved using drug-free in vitro activation (IVA).


   Case Report Top


A 34 year old female had reduced anti-mullerian hormone (AMH) levels of 0.22 ng/ml. Her antral follicle count in the left ovary was 1 and in the right ovary was 2. The ovarian volume right side was 6 cc and left side was 8.2 cc. Her FSH was 11.2 mIU/ml and had a history of irregular scanty periods. Despite diverse testing including chromosomal analysis, her pathogenesis was unknown. After counseling the patient about the procedure, the patient agreed and we further proceeded to take the approval of our Institutional Ethics Committee (ECR/842/Inst/GJ/2016/RR-20) approved the treatment, and the patient provided written and informed consent for Drug Free in vitro activation of Ovary procedure. To suppress serum gonadotropin levels before grafting ovarian fragments, pre-treatment with oral oestrogen/progesterone was given (21 day therapy).

We used a laparoscopic approach to extract the ovarian tissue. We opted to remove one-third of the right-sided ovarian cortex in an endobag. For the removal of the ovarian cortex, we used scissors and laparoscopic knife. The ovarian cortex was dissected into thin strips devoid of medullary portion with efforts to minimise any surgical trauma to the sensitive ovarian tissue, excluding the medullary portion as much as possible to minimise the surgical trauma to the sensitive ovarian tissue. Bipolar coagulation was not used on the medulla after the extraction of the ovarian cortex.

Embryology laboratory details

The ovarian cortex was dissected to remove residual medulla tissue. Tissue strips were then cut into small cubes (1 mm × 1 mm × 1 mm). These tiny pieces were loaded into a cannula. Histopathological analysis showed the presence of some residual follicles.

The autotransplantation was performed by laparoscopy in the same surgical procedure, and a small window (2 cm × 2 cm) was made below the right ovary and  Fallopian tube More Details, and small strips of ovarian cortical tissue were transferred into the window through a modified Ryle's tube wherein, the tube was cut before the first eye/hole at the distal end to facilitate smooth transfer of ovarian strips. The window was sutured with Vicryl 2.0. The patient was discharged on the same day of the surgery without any complications.

Pre-treatment with oestradiol/progesterone was stopped the day before ovary autografting, inducing withdrawal bleeding soon after the surgery. After initiation of withdrawal bleeding in November 2019, a baseline transvaginal sonography (TVS) revealed an antral follicle count of 3. An antagonist protocol was initiated with recombinant FSH (Folisurge and Intas Pharmaceuticals) and human menopausal gonadotropin (HMG) (IVFM, menotropin and L G Chem) and Cetrotide 0.25 mg, Merck Sereno Biopharmaceuticals, United Kingdom were added on day 7.

After 9 days of Ovarian Stimulation eight dominant follicles were noted of which six were on the right ovary and two in the left ovary were observed in transvaginal ultrasound. Recombinant human chorionic gonadotropin (ovitrelle 250; Merck, Spain) was administered, and 36 h later, oocyte retrieval was performed. Four mature oocytes were retrieved, fertilisation was achieved through intracytoplasmic sperm injection (ICSI) and 1 embryo of day 3 embryos was frozen Grade C.

In the next cycle in April 2020, stimulation was started with HMG (menotropin and Bayer Zydus Pharma Pvt Ltd). After 13 days of ovarian stimulation, seven dominant follicles were observed: four on the right side and three on the left side by transvaginal ultrasound. Dual trigger (ovitrelle 250; Merck, Spain and 0.1 mg of triptorelin acetate decapeptyl; Ferring pharmaceuticals) was given, and 36 h later, the oocyte retrieval was performed. However, no oocytes were retrieved. Further, treatment was delayed due to COVID-19 pandemic, and the third cycle was initiated in December 2020.

An AFC of four was noted, and stimulation of the third cycle was started in December 2020. Stimulation started with injection GnRH antagonist protocol United Kingdom.

After 9 days of ovarian stimulation, seven follicles were observed (right side: five follicles: 16, 17, 19, 19 and 17 mm and left side: two follicles: 19.19 mm) by TVS. Dual trigger (ovitrelle 250; Merck, Spain and 0.1 mg of triptorelin acetate decapeptyl; ferring pharmaceuticals) was administered and 36 h later, oocyte retrieval was performed. Three eggs from the right ovary and two eggs from the left ovary were retrieved. Fertilisation was achieved through ICSI, and three good quality day 3 embryo of Grade A, A and C were transferred. There was an increase in the AMH levels too which was 0.85 ng/ml. Singleton pregnancy was established with sonographic evidence of pregnancy observed at the 5th week. Cardiac activity was established in the 6th week.

The growth parameters were satisfactory until the 9th week of pregnancy after which, the cardiac activity stopped resulting miscarriage. We still have 01 embryo of day 3 frozen from the first cycle.


   Discussion Top


To our knowledge, this is the first case report from India documenting the efficacy of IVA work that has led to a pregnancy. POI patients have intermittent and unpredictable ovarian function due to the lack of follicles and ovulation. In general, in these patients, egg donation is the most widely used option to treat infertility. Thus, such development of new methods would enable patients to conceive using their own eggs. Many small studies have demonstrated that it is possible to activate dormant follicles within such ovaries and achieve pregnancy.[6],[2] It has been hypothesised that fragmentation of ovarian cortex interferes with the Hippo signalling pathway and leads to the production of growth factors to promote primordial to pre-antral follicular growth, but the specific mechanism of action responsible for the activation of dormant follicles has not been elucidated.[7]

In conclusion, IVA appears to be an attractive approach in the management of POI and DOR. However, it is to be highlighted that it is still an experimental procedure and larger studies are needed to ensure safety and efficacy.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initial will not be published and due efforts will be made to conceal her identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr Rev 2009;30:465-93.  Back to cited text no. 1
    
2.
Fabregues F, Ferreri J, Calafell JM, Moreno V, Borrás A, Manau D, et al. Pregnancy after drug-free in vitro activation of follicles and fresh tissue autotransplantation in primary ovarian insufficiency patient: A case report and literature review. J Ovarian Res 2018;11:76.  Back to cited text no. 2
    
3.
Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 2008;319:611-3.  Back to cited text no. 3
    
4.
Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A 2010;107:10280-4.  Back to cited text no. 4
    
5.
Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A 2013;110:17474-9.  Back to cited text no. 5
    
6.
Kawamura K, Ishizuka B, Hsueh AJ. Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. Reprod Biomed Online 2020;40:245-53.  Back to cited text no. 6
    
7.
Griesinger G, Fauser BC. Drug-free in-vitro activation of ovarian cortex; can it really activate the 'ovarian gold reserve'? Reprod Biomed Online 2020;40:187-9  Back to cited text no. 7
    




 

Top
Print this article  Email this article
             

    

 
   Search
 
  
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Article in PDF (523 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Case Report
   Discussion
    References

 Article Access Statistics
    Viewed866    
    Printed36    
    Emailed0    
    PDF Downloaded140    
    Comments [Add]    

Recommend this journal